Psoriasis-related juvenile idiopathic arthritis | UniteRare Disease Library

Overview

Also known as:

Juvenile psoriatic arthritis Psoriasis-related JIA

Clinical phenotype terms— hover any for plain English:

Abnormality of tumor necrosis factor secretionHP:0011118Nail pitsHP:0001803Psoriasiform dermatitisHP:0003765Polyarticular arthritisHP:0005764Finger dactylitisHP:0031090Toe dactylitisHP:0031091OligoarthritisHP:0040313EnthesitisHP:0100686Abnormal shoulder morphologyHP:0003043Generalized morning stiffnessHP:0005197

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events

Dec 2025Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.

Novartis Pharmaceuticals

TrialNOT YET RECRUITING

Sep 2025Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Novartis Pharmaceuticals — PHASE1

TrialRECRUITING

Mar 2025A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Bristol-Myers Squibb — PHASE3

TrialRECRUITING

Mar 2025An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

UCB Biopharma SRL — PHASE3

TrialRECRUITING

Oct 2024A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Janssen Research & Development, LLC — PHASE3

TrialRECRUITING

Jul 2024A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

AbbVie — PHASE3

TrialRECRUITING

Mar 2023A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Amgen — PHASE3

TrialRECRUITING

Aug 2022A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

Janssen Research & Development, LLC — PHASE3

TrialACTIVE NOT RECRUITING

Mar 2022Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

Amgen — PHASE3

TrialRECRUITING

Apr 2021A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Eli Lilly and Company — PHASE3

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

5 available

Enbrel

etanercept· Immunex Corporation■ Boxed Warning

indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA)

View Details →FDA Label ↗

SIMPONI ARIAï¿½

golimumab· Janssen Research & Development, LLC■ Boxed Warning

SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older

View Details →FDA Label ↗

OTEZLAï¿½

apremilast· Amgen Inc.

indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis

View Details →FDA Label ↗

HUMIRA

adalimumab· AbbVie, Inc.■ Boxed Warning

Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis

View Details →FDA Label ↗

Remicade

infliximab· Janssen Biotech, Inc.■ Boxed Warning

reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients

View Details →FDA Label ↗

Clinical Trials

8 recruitingView all trials with filters →

Phase 37 trials

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Phase 3

Actively Recruiting

PI: UCB Cares (001 844 599 2273) · Sites: Calgary; Montreal +21 more · Age: 2–18 yrs

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Phase 3

Actively Recruiting

PI: ABBVIE INC. (AbbVie) · Sites: Little Rock, Arkansas; Washington D.C., District of Columbia +29 more · Age: 5–17 yrs

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Phase 3

Actively Recruiting

PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Lancaster, California; Chicago, Illinois +45 more · Age: 5–17 yrs

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Phase 3

Actively Recruiting

PI: MD (Amgen) · Sites: Thessaloniki; Kfar Saba +5 more · Age: 5–18 yrs

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

Phase 3

Actively Recruiting

PI: MD (Amgen) · Sites: Bregenz; Ghent +43 more · Age: 5–17 yrs

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

Phase 3

Active

PI: Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC) · Sites: Los Angeles, California; Los Angeles, California +48 more · Age: 5–17 yrs

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Phase 3

Active

PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company) · Sites: Rosario, Santa Fe Province; San Miguel de Tucumán, Tucumán Province +41 more · Age: 2–17 yrs

Phase 11 trial

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Phase 1

Actively Recruiting

· Sites: Gainesville, Florida; Chicago, Illinois +5 more · Age: 2–17 yrs

Specialists

2 foundView all specialists →

Michelle Batthish, MD

Specialist

Juvenile dermatomyositis Juvenile idiopathic inflammatory myopathy Juvenile polymyositis

PI on 1 active trial

Active trials Directions Travel grants

Megan L Fitzgerald, PhD

Delafield, Wisconsin

Specialist

Rare Disease Specialist

Chronic encephalitis Ehlers-Danlos syndrome Genetic primary orthostatic disorder+9 more

PI on 1 active trial

Active trials Directions Travel grants

Treatment Centers

8 centers

🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources

Marbeta L Kit

Marnel

Psoriasis and Eczema

Unverified — confirm before calling

copay card

Copay CardPatient Assistance

Accepting applications

Rinvoq

AbbVie, Inc.

Rinvoq Patient Support (AbbVie Patient Assistance)

Patient Assistance

Manufacturer Program

Accepting applications

Apply

Travel Grants

No travel grants are currently matched to Psoriasis-related juvenile idiopathic arthritis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Psoriasis-related juvenile idiopathic arthritisForum →

No community posts yet. Be the first to share your experience with Psoriasis-related juvenile idiopathic arthritis.

Start the conversation →

Latest news about Psoriasis-related juvenile idiopathic arthritis

Disease timeline:

New recruiting trial: Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

A new clinical trial is recruiting patients for Psoriasis-related juvenile idiopathic arthritis

New recruiting trial: A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

A new clinical trial is recruiting patients for Psoriasis-related juvenile idiopathic arthritis

New recruiting trial: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

A new clinical trial is recruiting patients for Psoriasis-related juvenile idiopathic arthritis

New recruiting trial: Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

A new clinical trial is recruiting patients for Psoriasis-related juvenile idiopathic arthritis

New trial: A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including

Phase PHASE3 trial recruiting. Placebo

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Psoriasis-related juvenile idiopathic arthritis

Are there clinical trials for Psoriasis-related juvenile idiopathic arthritis?

Yes — 8 recruiting clinical trials are currently listed for Psoriasis-related juvenile idiopathic arthritis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Psoriasis-related juvenile idiopathic arthritis?

2 specialists and care centers treating Psoriasis-related juvenile idiopathic arthritis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Psoriasis-related juvenile idiopathic arthritis?

2 patient support programs are currently tracked on UniteRare for Psoriasis-related juvenile idiopathic arthritis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.